BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Madrigal's blockbuster drug gaining FDA approval this March ha
 s opened the doors to a wave of therapeutics from Eli Lilly\, Boehringer 
 Ingelheim\, AstraZeneca\, Amgen\, Akero Therapeutics and more that hold h
 uge promise in Phase 1\, 2\, and 3 clinical trials. Paired with the boom 
 of GLP-1s\, these milestones have reinvigorated investment throughout the
  metabolic space.\n\nThe 8th MASH Drug Development Summit is the perfect 
 forum to unite and discuss the evolving drug development opportunity for 
 MASH and metabolic diseases. From optimizing clinical trial design to ove
 rcoming regulatory challenges\, combatting fibrosis\, navigating GLP-1 us
 age\, optimizing RWE integration and achieving accurate non-invasive biom
 arkers\, you won't find this industry-led insight anywhere else.\n\nJoin 
 120+ C-Level cardiometabolic stakeholders and thought leaders to make key
  connections\, gain competitive insights and hear the latest data to shap
 e the future of your MASH development pipeline.\n\nURLs:Tickets: https://
 go.evvnt.com/2611979-2?pid=185Brochure: https://go.evvnt.com/2611979-3?pi
 d=185\n\nTime: 8:00 AM - 4:15 PM\n\nSpeakers: Adam Bell\, Vice President\
 , Neuraly\, Bonnie Fendrock\, Chief Executive Officer and Co-founder\, Cy
 ta Therapeutics\, Charlotte Scott\, Professor\, Ghent University\, Cynthi
 a Arbeeny\, CSO\, Mitotherapeutix\, David Brenner\, Chief Executive Offic
 er\, Sanford Burnham Prebys\, David Lloyd\, Vice President\, Insitro\, Ez
 ra Lowe\, Vice President\, Galectin Therapeutics\, François Briand\, Dire
 ctor - Research and Business Development\, Physiogenex\, Gerald Horan\, S
 enior Scientific Director\, Bristol Myers Squibb\, Hank Mansbach\, Chief 
 Medical Officer\, 89 Bio\, Jay Kim\, Chief Executive Officer\, Therasid B
 io\, Jeff McIntyre. President\, Global Liver Institute\, Jerry Colca\, Ch
 ief Scientific Officer\, Cirius\, Jingyu (Julia) Luan\, Senior Director\,
  AstraZeneca\, Kai-Min Chu\, Chief Executive Officer\, Sinew\, Katarina W
 ikstrom\, Global VP Product Development\, Almac\, Kathleen Elias\, Co-fou
 nder\; Vice President - Research and Translational Medicine\, Seal Rock T
 herapeutics\, Kristin Fiorino\, Medical Director\, AstraZeneca\, Lichuan 
 Yang\, Senior Director - Disease Model Development and Biomarkers\, KBI\,
  Manu Chakravarthy\, SVP and Global Head of Cardiovascular\, Renal and Me
 tabolism Product Development\, Carmot\, Maria Trujillo\, Senior Principal
  Scientist\, Merck\, Matt Bryant\, Vice President\, Boston Pharmaceutical
 s\, Meena Bansal\, Professor of Medicine\, Mount Sinai\, Michael Cooreman
 \, Chief Medical Officer\, Inventiva\, Miriam Kidron\, Chief Scientific O
 fficer\, Oramed\, Oliver Yoa-Pu Hu\, Professor\, Taiwan University\, Pitc
 humani Sivakumar\, Director Translational Medicine\, Pfizer\, Rebecca Tau
 b\, Chief Medical Officer\, Madrigal\, Reshma Shringarpure\, Vice Preside
 nt\, Akero\, Rosemarie Sellati\, Director\, Regeneron\, Sarah Wills\, Dir
 ector\, AstraZeneca\, Scott Harris\, Chief Medical Officer\, Altimmune\, 
 Sherrie Pietranico Cole\, Senior Director\, Regeneron\, Sophie Jeannin\, 
 Chief Medical Officer\, Summit Clinical Research\, Stephanie Watkins\, Se
 nior Director\, Gilead\, Tatiana Kisseleva\, Associate Professor\, Univer
 sity of California\, Thomas Fabre\, Senior Principal Scientist - Fibrosis
 \, Pfizer\, Yao-Yao Zhu\, Director\, Global Regulatory Affairs\, AstraZen
 eca\n
DTEND:20240926T161500
DTSTAMP:20260512T220025Z
DTSTART:20240924T080000
LOCATION:Hilton Boston Logan Airport\, One\, Hotel Drive\, Boston\, Massac
 husetts\, 02128\,
SEQUENCE:0
SUMMARY:Madrigal's blockbuster drug gaining FDA approval this March has op
 ened the doors to a wave of therapeutics from Eli Lilly\, Boehringer Inge
 lheim\, As...
UID:46f1e8be-35c6-4126-8031-5202aed50edc
END:VEVENT
END:VCALENDAR